SI-BONE (SIBN) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.08
- Estimate
- -$0.13
- Surprise
- +37.6%
- Score today
- 5.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
SI-BONE (SIBN) reported a narrower loss than forecast — adjusted EPS of -$0.08 against the -$0.13 estimate (a 37.6% beat on a still-unprofitable quarter).
Coverage in the report window
- SI-BONE Q3 2026 Earnings Call Transcript — benzinga, 2026-11-02
- SI-BONE, Inc. Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-02
- SI-BONE Affirms FY2026 Sales Guidance of $231.000M-$233.000M vs $232.024M Est — benzinga, 2026-11-02
Where TrendMatrix's rating stands now
TrendMatrix currently rates SIBN Sell at 5.7/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +37.6% surprise compares with a +48.3% four-quarter average.
What argues against it
- Quality below floor (3.4 < 4.0)
- Value-trap signals (2/5): Revenue declining (-7.6% YoY), Margin compression (op margin -142.6%)
- Reward/Risk 1.1:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $20.22
- Price target
- $22.14
- Stop
- $18.80
- Upside to target
- +9.5%
- Reward-to-risk
- 1.1:1
Risk check: trading volume is running 2.1× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-03 — shown for context, not personalized investment advice.
SIBN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $896.7M
- P/E (fwd)
- -61.1
- 52-week range
- $11.48–$22.95
- Off 52-week high
- 11.9%
- RSI (14)
- 54
- Volume vs avg
- 2.09×
- Score today
- 5.7/10